## Vitamin A Deficiency & Xerophthalmia in Children ### Xerophthalmia Staging **Key Point:** Xerophthalmia is staged X1A → X1B → X2 → X3A → X3B → CS (corneal scar), with X1B representing Bitot's spots and early corneal involvement. | Stage | Clinical Finding | Reversibility | |-------|------------------|----------------| | **X1A** | Night blindness only | Fully reversible | | **X1B** | Night blindness + Bitot's spots ± corneal haze | Fully reversible | | **X2** | Corneal opacity (< 1/3 of cornea) | Reversible with urgent treatment | | **X3A** | Corneal opacity (≥ 1/3 of cornea) | Risk of scarring | | **X3B** | Corneal scarring | Irreversible blindness | | **CS** | Corneal scar (healed) | Irreversible | ### High-Dose Vitamin A Therapy (WHO/ICMR Protocol) **High-Yield:** High-dose retinol palmitate is the gold standard for xerophthalmia stages X1B and beyond to prevent progression to corneal scarring and blindness. ### Dosing Regimen for X1B **Clinical Pearl:** The WHO recommends: - **Day 1:** Retinol palmitate 200,000 IU orally - **Day 2:** Repeat 200,000 IU - **Day 14:** Repeat 200,000 IU (at 2 weeks) - **Maintenance:** Age-appropriate RDA after acute phase This high-dose, pulsed approach rapidly restores retinoid stores and halts progression. ### Why High-Dose Over Maintenance Dosing? 1. **Urgency:** Corneal involvement (even haze) signals risk of rapid progression to scarring within days. 2. **Tissue saturation:** High-dose therapy rapidly replenishes hepatic and ocular retinoid pools. 3. **Prevention of blindness:** Prevents advancement from X1B → X2 → X3 → CS. ### Route & Formulation - **Oral:** Preferred in cooperative, non-vomiting children (retinol palmitate suspension). - **IM:** Reserved for malabsorption, vomiting, or severe protein-energy malnutrition. **Mnemonic:** BITOT = **B**lind prevention **I**mmediately **T**herapy **O**ral **T**reatment (high-dose)
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.